Document 3QZLLZNdQjvqzXRxEOzo15ndE

Message From: Janet Collins [jcollins@croplifeamerica.org] Sent: 4/13/2018 6:12:42 PM To: Beck, Nancy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=168ecb5184ac44de95a913297f353745-Beck, Nancy]; Keigwin, Richard [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=151baabb6a2246a3a312fl2a706c0a05-Richard P Keigwin Jr] CC: csmith@gowanco.com [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85a93dee627e495997f325593ed303eb-csmith@gowa] Attachments: martytal oxon paper 2012.pdf Dear Nancy and Rick- thank you for the time you dedicated to meeting with us on Wednesday morning. During the meeting, we discussed the EPA consideration of the exposure information from the CHAMACOS study. We discussed that CHAMACOS did not report chlorpyrifos but did report on the oxons of chlorpyrifos. Attached please find a paper published in 2012 wherein you will note the authors statement (see last sentence in abstract) that oxons would not be in the peripheral tissues- thus, would not be present in the brain- brain function would not then be affected by oxons in the blood samples. We welcome the opportunity to discuss this further, and likely will address that specific point when we provide the final study report that we have conducted to plot the data from the Columbia University study. Thank you again. My best Janet E Collins, Ph.D., R.D. Executive Vice President, Science and Regulatory Affairs CropLife America 1156 15th Street, NW; Suite 400 Washington DC 20001 Ex. 6 Sierra Club v. EPA 18cv3472 NDCA Tier 3/4 ED 002061 00045667-00001